FDA.reportPublic FDA data

Nuvaxovid 2025-2026 vaccine 0.5 ML Prefilled Syringe

RxCUI
2723014
RxNorm name
Nuvaxovid 2025-2026 vaccine 0.5 ML Prefilled Syringe
Display name
Nuvaxovid 2025-2026 vaccine 0.5 ML Prefilled Syringe
Full name
Nuvaxovid 2025-2026 vaccine 0.5 ML Prefilled Syringe
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:48

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125817NUVAXOVIDCOVID-19 Vaccine, Adjuvanted351(a)Rx2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
1a20513c-d255-46d7-8e6b-294cec4b44f4NUVAXOVID 2025-2026 vaccine 0.5 ML Prefilled Syringe [PSN] · 0.5 ML SARS-CoV-2 (COVID-19) vaccine, protein NVX-CoV2705 0.01 MG/ML Prefilled Syringe [Nuvaxovid 2025-2026] [SBD] · Nuvaxovid 2025-2026 vaccine 0.5 ML Prefilled Syringe [SY]33These highlights do not include all the information needed to use NUVAXOVID safely and effectively. See full prescribing information for NUVAXOVID. NUVAXOVID TM (COVID-19 Vaccine, Adjuvanted) injectable suspension, for intramuscular use 2025-2026 Formula Initial U.S. Approval: 202520250827